U.S. Urology Devices Market to Hit USD 9.50B by 2035

Market Outlook

By 2035, the U.S. Urology Devices Market is expected to reach approximately USD 9.50 billion, growing at a CAGR of 6.80% during the forecast period 2026-2035. The market was valued at USD 4.92 billion in 2025, with historical analysis from 2021 to 2024. Values in this report are expressed in USD billions. The forecast represents a urology-specific device scope that includes endoscopy and visualization systems, stone-management products, urinary drainage and access devices, benign prostatic hyperplasia treatment platforms, continence and pelvic-floor technologies, urodynamic systems, and procedure-linked robotic and surgical equipment. Chronic dialysis equipment and general-purpose imaging systems are excluded unless revenue can be directly attributed to urology workflows.

The U.S. urology devices industry is supported by a large and clinically diverse patient base. Kidney stones affect about 11% of U.S. men and 6% of women at least once during their lifetime. Benign prostatic hyperplasia and associated lower urinary tract symptoms affect approximately 5% to 6% of men aged 40-64 and roughly 29% to 33% of men aged 65 and older. Urinary incontinence is also materially underdiagnosed: national survey evidence indicates that about 54% of adult women and 15% of adult men report symptoms over a 12-month period. These conditions generate recurring demand for cystoscopes, ureteroscopes, laser fibers, guidewires, retrieval baskets, access sheaths, catheters, stents, continence implants, neuromodulation systems, urodynamic equipment, and minimally invasive prostate-treatment devices.

Urologic cancer further strengthens the procedural base. U.S. estimates for 2026 include approximately 333,830 new prostate cancer cases, 84,530 bladder cancer cases, and 80,450 kidney and renal pelvis cancer cases. Prostate cancer remains the largest cancer diagnosis by incidence in the country, while bladder cancer creates repeated surveillance demand because many patients require long-term cystoscopy, biopsy, resection, intravesical treatment support, and recurrence monitoring. Kidney and renal pelvis cancer supports robotic partial nephrectomy, laparoscopic instruments, ablation systems, access devices, and advanced visualization. The commercial opportunity therefore extends beyond one-time treatment and includes high-frequency diagnostic, therapeutic, and follow-up episodes.

The market is moving from conventional reusable instruments and broad electrosurgical platforms toward a mixed ecosystem of single-use endoscopes, high-power laser lithotripsy, suction-enabled stone evacuation, robotic waterjet resection, office-based BPH procedures, rechargeable or long-life neuromodulation implants, digital urodynamics, and robotic-assisted oncology surgery. Hospital purchasing decisions are increasingly based on total procedural economics rather than acquisition price alone. Technologies that reduce operating-room time, lower infection and reprocessing risk, shorten catheterization, support same-day discharge, reduce unplanned hospital visits, and expand use in ambulatory surgery centers are receiving stronger value-analysis support.

The historical market expanded from USD 3.76 billion in 2021 to USD 4.66 billion in 2024. The estimated series reached USD 4.05 billion in 2022 and USD 4.40 billion in 2023 as elective procedure volumes normalized, supply constraints eased, and hospitals resumed investment in endoscopy towers, lasers, robotics, and urology service-line capacity. In 2025, the market reached USD 4.92 billion, supported by faster adoption of disposable ureteroscopes, modern BPH platforms, sacral neuromodulation, robotic surgery systems, premium stone-management consumables, and site-of-care migration. By 2030, the market is projected to approach USD 6.84 billion, before reaching USD 9.50 billion in 2035 as capital placements generate recurring procedure-linked consumable revenue.

Introduction

According to the U.S. Urology Devices Market Report, the market is shaped by a combination of population aging, high metabolic disease prevalence, advanced surgical infrastructure, established Medicare coverage, and continuous procedural innovation. The U.S. population aged 65 and older reached approximately 61.2 million in 2024 and is expanding faster than the overall population. This demographic shift directly increases the prevalence of BPH, urinary retention, urinary incontinence, overactive bladder, prostate cancer, bladder cancer, and complex stone disease. It also changes device requirements because older patients often need shorter procedures, lower anesthesia exposure, reduced bleeding risk, simplified postoperative care, and technologies that can be used safely across multiple comorbidities.

The U.S. urology devices market is not a single product category. It combines capital equipment, reusable endoscopes, single-use scopes, implantable devices, high-volume consumables, drainage products, diagnostic platforms, and software-enabled surgical systems. Mature categories such as Foley catheters, ureteral stents, guidewires, cystoscopes, resectoscopes, and retrieval baskets provide a stable demand base. Faster-growth categories such as thulium fiber lasers, suction access sheaths, disposable ureteroscopes, robotic BPH systems, sacral neuromodulation, office-based prostate implants, and next-generation surgical robotics add premium expansion. This balanced mix makes the market resilient while still creating meaningful opportunities for technology-led share shifts.

The market is deeply linked to U.S. provider economics. The country has approximately 6,100 hospitals, more than 907,000 staffed beds, and over 35 million annual hospital admissions. It also has more than 6,400 Medicare-certified ambulatory surgery centers, a setting increasingly relevant for cystoscopy, ureteroscopy, lithotripsy, transurethral procedures, continence interventions, and selected prostate treatments. Large health systems often standardize urology products across multiple hospitals and ASCs, while independent urology groups may control procedure choice through physician ownership, office-based laboratories, or joint-venture ambulatory facilities. Manufacturers must therefore sell to both clinical champions and financially disciplined procurement organizations.

Specialist availability is another important structural factor. The 2025 U.S. urology workforce included approximately 14,609 practicing urologists, yet most U.S. counties did not have a practicing urologist. This geographic imbalance creates a two-speed market. Major metropolitan and academic centers adopt advanced robotics, laser platforms, and complex oncology technologies. Rural and underserved markets place greater value on portable diagnostics, disposable scopes, tele-support, durable drainage products, and systems that reduce dependence on highly specialized reprocessing or technical staff. Device companies that can serve both high-acuity referral centers and lower-resource community settings will have a larger addressable market.

From 2026 to 2035, the central strategic theme will be the conversion of urology from a predominantly hospital-based surgical specialty into a distributed procedural network spanning hospitals, ASCs, office procedure suites, imaging centers, and the home. The winning platforms will support patient identification, diagnosis, intervention, follow-up, and outcomes documentation across these settings. Buyers will increasingly favor technologies that create predictable case economics, reduce staff burden, integrate with existing towers or robotic fleets, and generate measurable improvement in throughput and patient recovery.

Key Market Drivers: What’s Fueling the U.S. Urology Devices Market Boom?

The first major driver is the scale and persistence of urologic disease in an aging population. BPH, urinary incontinence, overactive bladder, urinary retention, kidney stones, and urologic cancers are not isolated conditions; they frequently coexist with diabetes, obesity, hypertension, chronic kidney disease, cardiovascular disease, and mobility limitations. More than 37 million U.S. adults are estimated to have chronic kidney disease, and many remain unaware of their condition. Although chronic dialysis equipment is outside the core scope of this report, the wider renal disease burden increases demand for urinary drainage, obstruction management, stenting, imaging, stone intervention, and infection-control products. Aging also increases repeat utilization because many patients require surveillance, device replacement, staged procedures, or long-term catheter and continence management.

A second driver is the shift in kidney-stone treatment toward endoscopic, laser-based, and actively evacuated workflows. Claims data show that computed tomography is used in most diagnosed stone episodes, while extracorporeal shock-wave lithotripsy use has declined over time. Ureteroscopy has gained clinical preference because it offers direct visualization, flexible access, higher stone-free potential in selected patients, and compatibility with modern laser systems. This supports recurring demand for ureteroscopes, laser fibers, guidewires, baskets, access sheaths, stents, irrigation devices, and suction-enabled systems. The economics are especially attractive for manufacturers because a capital laser or visualization placement can anchor a long stream of procedure-specific consumables.

A third driver is the conversion of symptomatic BPH patients from medication management to minimally invasive procedural treatment. BPH is the most common prostate problem in men older than 50, yet many patients remain on medications despite inadequate symptom control, sexual side effects, or progressive obstruction. U.S. claims data already show a movement toward minimally invasive surgical therapies. Prostatic urethral lift, convective water-vapor therapy, laser enucleation or vaporization, robotic waterjet resection, and other tissue-removal approaches compete across prostate size, anatomy, durability, sexual-function preservation, and care setting. As more urology groups build office and ASC procedure capacity, the treated population can expand beyond patients who would accept traditional transurethral resection.

A fourth driver is the unmet need in urinary incontinence and overactive bladder. Symptoms are common, stigmatized, and often undertreated. The treatment pathway can include diagnostic urodynamics, pelvic-floor therapy, injectable bulking agents, slings, artificial urinary sphincters, botulinum toxin delivery, tibial nerve stimulation, and sacral neuromodulation. Device adoption is supported by the chronic nature of the condition and by the failure of many patients to remain on oral medication. Neuromodulation platforms are particularly attractive because they create an implantable-device market with recurring lead, trial, programming, replacement, and follow-up activity. The Boston Scientific acquisition of Axonics also demonstrates that large medtech companies view continence care as a strategic growth platform rather than a niche category.

A fifth driver is the large urologic oncology procedure base and the continued expansion of robotic-assisted surgery. Radical prostatectomy, partial nephrectomy, cystectomy, lymph-node dissection, and reconstructive procedures are technically demanding and are increasingly performed with robotic assistance in high-volume U.S. centers. The installed base creates recurring revenue from instruments, accessories, service contracts, imaging integration, and training. The entry of newer robotic systems expands hospital choice and can accelerate capital replacement cycles, especially where health systems want to increase operating-room capacity, reduce single-vendor dependence, or standardize across multiple campuses.

A sixth driver is site-of-care migration. Medicare-certified ASCs increased to 6,436 facilities in 2024, and CMS continues to update the ASC covered-procedure and payment framework. Urology is well positioned for outpatient migration because many procedures are short, repeatable, and compatible with same-day discharge. Ureteroscopy, cystoscopy, prostate biopsy, shock-wave lithotripsy, selected BPH procedures, stent placement and removal, urethral dilation, and continence interventions can be delivered outside the inpatient setting when patient selection is appropriate. Manufacturers that provide compact equipment, rapid setup, low reprocessing burden, predictable disposable cost, and strong reimbursement support are gaining an advantage in ASC and office-based procurement.

A seventh driver is hospital capital procurement behavior. Urology service lines compete for capital against orthopedics, cardiology, imaging, and general surgery. A device must therefore demonstrate more than clinical novelty. Procurement committees evaluate expected case volume, contribution margin, reimbursement, maintenance expense, staff training, reprocessing, infection risk, room turnover, and the ability to retain or recruit surgeons. Capital-light placements, leasing, per-procedure pricing, bundled consumables, and enterprise contracts are becoming more important. Companies that can show a clear pathway from installed base to recurring utilization will be favored over stand-alone products without workflow or economic support.

An eighth driver is regulatory and quality pressure. Flexible endoscopes require rigorous cleaning and high-level disinfection, while damage, repair, and incomplete reprocessing can create hidden costs. Single-use cystoscopes and ureteroscopes are gaining adoption where health systems seek more predictable performance or infection-control simplification. At the same time, FDA clearance alone is not sufficient for broad adoption. U.S. buyers expect clinical evidence, post-market reliability, cybersecurity controls for connected systems, service responsiveness, and transparent economic modeling. The most successful manufacturers will combine regulatory execution with real-world evidence and credible implementation support.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. urology devices market is increasingly focused on standardizing outcomes while reducing procedural variability. The next competitive cycle is not simply about a sharper instrument or higher-resolution image. It is about creating an integrated workflow that helps clinicians plan treatment, navigate anatomy, remove tissue or stones efficiently, minimize complications, and document the result. This favors platform companies that combine capital equipment, disposables, software, service, and clinical education.

Single-use endoscopy is one of the most visible innovation areas. Disposable cystoscopes and ureteroscopes eliminate repair variability and reduce reprocessing requirements, while guaranteeing a new scope for each case. Their economics are strongest in low-volume sites, emergency coverage, after-hours procedures, isolation cases, and facilities with high repair expense. Reusable scopes remain competitive in high-volume centers with efficient reprocessing and strong asset utilization. The market is therefore not moving to one universal model; it is developing a hybrid fleet strategy in which health systems match reusable and single-use devices to case complexity, location, staffing, and infection-control requirements.

Stone-management innovation is moving toward higher energy efficiency, smaller fibers, improved deflection, better visualization, and active fragment evacuation. Thulium fiber lasers are competing with modern holmium systems by offering flexible pulse settings and compatibility with small-diameter fibers. Suction-enabled access sheaths and direct-in-scope suction aim to improve intrarenal visibility, manage pressure, and remove dust or fragments. Digital ureteroscopes and disposable platforms are also improving image quality and ergonomics. The commercial winner will not necessarily be the highest-power laser; it will be the system that produces consistent stone-free outcomes with manageable procedure time and consumable cost.

BPH treatment is becoming a major innovation battleground. Robotic waterjet resection combines real-time imaging, surgeon-defined planning, and automated tissue removal. The FDA clearance of the HYDROS robotic system in 2024 introduced AI-supported treatment planning, integrated ultrasound and cystoscopy, and a more streamlined operating-room footprint. Office and ASC-based technologies continue to improve as well, targeting faster recovery, reduced catheter use, preservation of sexual function, and treatment across broader prostate anatomies. Competition will increasingly be based on durability, retreatment rates, anesthesia requirements, and total cost over multiple years rather than only immediate symptom improvement.

Surgical robotics is entering a new phase. The da Vinci 5 platform received U.S. clearance in 2024 with upgraded computing, ergonomics, and force-sensing capabilities. Medtronic received U.S. clearance for the Hugo robotic-assisted surgery system for urologic procedures in late 2025, followed by initial commercial use in 2026. These developments create a more competitive capital market for prostatectomy, partial nephrectomy, cystectomy, and reconstructive urology. Hospitals will compare not only clinical capability but also room footprint, modularity, fleet utilization, instrument economics, data architecture, training burden, and compatibility with existing operating-room infrastructure.

Continence technology is advancing through longer-life implantable pulse generators, MRI-compatible systems, simplified programming, improved patient controllers, and minimally invasive bulking products. The next stage will emphasize patient selection and longitudinal management. Systems that combine trial-phase data, remote symptom tracking, programming support, and integration with electronic records can reduce clinic burden and improve conversion from evaluation to implant. Artificial urinary sphincters and male slings remain important for post-prostatectomy incontinence, while female stress incontinence continues to support slings and urethral bulking despite changing utilization patterns.

Digital and AI-enabled urology is emerging across imaging, robotics, pathology, urodynamics, and follow-up. AI-supported ultrasound interpretation can assist prostate treatment planning. Computer vision can support surgical video review and workflow analytics. Connected urodynamic systems can standardize testing and improve data storage, while remote bladder diaries and home monitoring can make symptom assessment more objective. Adoption will depend on validation, interoperability, privacy, and the ability to save clinician time. Software that adds measurable value to an existing device platform is more likely to be funded than stand-alone analytics without a clear reimbursement or workflow pathway.

Manufacturers are also raising the bar through evidence generation and service design. U.S. hospitals increasingly expect randomized studies, multi-year durability data, real-world registries, infection-control analysis, and economic evidence. Training is becoming a commercial capability in its own right because newer technologies require surgeon credentialing, staff education, and case-support infrastructure. Companies that can shorten the learning curve and help a provider build a sustainable procedure program will have stronger retention than companies that compete only on product specifications.

Segmentation Insights

The U.S. Urology Devices Market is segmented on the basis of product category, application, end user, technology type, and region. The segmentation reflects how U.S. buyers evaluate the market: by the clinical problem being treated, the procedural setting, the capital-consumable relationship, and the degree of workflow transformation required.

By Product Category

Urology endoscopes and visualization systems represent one of the largest and most strategically important product categories. The segment includes reusable and single-use cystoscopes, flexible and semi-rigid ureteroscopes, nephroscopes, resectoscopes, video processors, camera heads, light sources, monitors, and related imaging accessories. Demand is supported by stone disease, hematuria evaluation, bladder-cancer surveillance, ureteral obstruction, urethral stricture, and transurethral prostate procedures. Reusable platforms remain dominant in high-volume hospitals, but single-use scopes are gaining share in ASCs, emergency departments, satellite sites, and systems seeking to reduce repair and reprocessing variability.
Stone-management devices form a high-volume consumable category that includes laser lithotripsy systems, laser fibers, shock-wave lithotripters, guidewires, retrieval baskets, access sheaths, dilators, stone cones, nephrostomy products, irrigation systems, and suction-enabled evacuation devices. Growth is shifting toward flexible ureteroscopy, miniaturized percutaneous procedures, high-power lasers, and active evacuation. The segment benefits from repeat stone episodes and strong procedural standardization. Vendor share is influenced by scope-laser compatibility, fiber performance, basket design, access-sheath ergonomics, and the ability to provide a complete stone pathway rather than isolated products.
Urinary drainage, access, and reconstruction devices provide a stable base of recurring demand. This category includes Foley and intermittent catheters, coude catheters, suprapubic drainage products, nephrostomy catheters, ureteral stents, drainage bags, introducers, dilators, guidewires, and urethral reconstruction accessories. Hospitals, long-term care providers, home-health organizations, and urology practices purchase these products in large volumes. Competition is highly sensitive to infection prevention, coatings, patient comfort, insertion ease, supply reliability, and contracting. Premium growth is concentrated in hydrophilic intermittent catheters, antimicrobial strategies, patient-friendly packaging, and home-use support.
BPH and prostate-treatment devices are among the fastest-growing categories. The segment includes prostatic urethral lift implants, water-vapor systems, robotic waterjet resection, laser enucleation and vaporization platforms, electrosurgical resection systems, temporary implantable devices, balloon technologies, and associated imaging or delivery products. The addressable market is expanding because many symptomatic men remain managed with medication or watchful waiting. Product selection depends on prostate size, anatomy, bleeding risk, sexual-function priorities, anesthesia tolerance, expected durability, and site of service. Technologies that can expand office or ASC treatment while maintaining durable outcomes are positioned for premium growth.
Urinary incontinence and pelvic-floor devices include sacral neuromodulation systems, percutaneous tibial nerve stimulation equipment, artificial urinary sphincters, male and female slings, urethral bulking delivery systems, pessary-related products, pelvic-floor stimulation devices, and procedure accessories. The segment is clinically fragmented but commercially attractive because symptoms are common and medication persistence is poor. Sacral neuromodulation is the highest-value implantable subsegment, while bulking agents and office-based stimulation can expand lower-acuity access. Adoption depends on referral pathways, patient education, trial-to-implant conversion, and physician comfort with long-term follow-up.
Urodynamic and diagnostic devices include urodynamic analyzers, uroflowmetry systems, bladder scanners, pressure catheters, electromyography accessories, ultrasound systems dedicated to urology, prostate biopsy devices, and urine-flow or residual-volume measurement tools. This category is smaller by revenue but strategically important because it supports diagnosis, treatment selection, and documentation. Bladder scanners are widely used beyond urology in nursing, emergency, perioperative, rehabilitation, and long-term care settings. Digital connectivity, automatic interpretation, portable form factors, and lower training requirements are key differentiators.
Urologic surgical, robotic, and energy systems include robotic-assisted surgery platforms, urology-specific robotic systems, electrosurgical generators, morcellators, tissue-removal devices, laparoscopic instruments, specimen retrieval, ablation equipment, and service contracts attributable to urologic procedures. This is the most capital-intensive category and one of the fastest-growing by value. Revenue is concentrated among a small number of companies, but the installed base supports substantial recurring instrument and accessory sales. Hospitals evaluate these systems through multi-year utilization models and often require cross-specialty use to justify capital, except when a dedicated urology platform has a strong per-procedure economic case.

By Application

Kidney stone and urinary stone disease management is the largest application segment by procedure-linked consumable volume. It includes diagnosis, ureteroscopy, laser lithotripsy, shock-wave lithotripsy, percutaneous nephrolithotomy, stone extraction, stenting, and postoperative removal. The South historically has a high stone burden, although recent claims data also show high prevalence among older adults in the Northeast. Growth is being driven by recurrent disease, obesity, diabetes, dehydration risk, and preference for endoscopic treatment. Manufacturers that connect imaging, scopes, lasers, evacuation, and stenting can capture a larger share of each episode.
Benign prostatic hyperplasia and lower urinary tract symptom management is the fastest-growing large application. The treated population is expanding as minimally invasive options reduce the psychological and clinical barriers associated with traditional surgery. The application includes diagnostic cystoscopy, residual-volume measurement, transurethral resection, laser treatment, prostatic implants, thermal therapy, and robotic waterjet resection. Commercial success depends on building referral pathways from primary care, supporting patient education, and helping providers match technology to anatomy and symptom severity.
Urinary incontinence, overactive bladder, and retention management combines chronic diagnosis, conservative treatment, office procedures, and implantable therapy. The application includes urodynamics, bladder scanning, catheters, neuromodulation, slings, sphincters, bulking agents, and injection support. Demand is particularly strong among older adults, women after childbirth, patients with neurologic disease, and men after prostate surgery. Because symptoms are often underreported, market growth depends on screening and referral as much as technology innovation.
Urologic oncology is a high-value application spanning prostate, bladder, kidney, ureteral, testicular, and penile cancers. The device mix includes cystoscopes, resectoscopes, biopsy systems, robotic surgery platforms, laparoscopic instruments, ablation systems, ureteral stents, nephrostomy products, and surveillance equipment. Prostate cancer drives robotic surgery and biopsy demand, bladder cancer drives repeated cystoscopic surveillance and transurethral resection, and kidney cancer supports partial nephrectomy and ablation. Academic centers and large cancer programs are important early adopters because they manage complex cases and clinical trials.
Urinary obstruction, stricture, infection, and reconstructive urology includes urethral dilation, internal urethrotomy, ureteral stenting, nephrostomy, drainage, reconstruction, and management of complex postoperative or congenital conditions. The segment is less visible than BPH or stone care but provides stable demand for access products, catheters, stents, endoscopy, and surgical instruments. Innovation opportunities include drug-coated balloons, improved stent materials, biodegradable concepts, pressure management, and devices that reduce repeat intervention.

By End User

Hospitals and integrated delivery networks are the dominant end users by value. They account for most robotic surgery, complex stone intervention, inpatient drainage, urologic oncology, advanced endoscopy, and high-acuity reconstruction. Large systems use value-analysis committees and enterprise contracts to standardize vendors, reduce inventory, and negotiate service terms. Their procurement decisions can determine national access for a manufacturer, particularly when one system controls multiple hospitals, ASCs, and physician groups.
Ambulatory surgery centers are the fastest-growing institutional end user. ASCs prioritize compact equipment, rapid turnover, predictable disposables, lower service complexity, and clear reimbursement. Ureteroscopy, lithotripsy, cystoscopy, selected BPH procedures, stent management, and continence interventions fit the model. The main limitation is that some advanced procedures require hospital backup, intensive anesthesia, or expensive capital that is difficult to justify without sufficient volume.
Urology group practices and office procedure centers are strategically important because physician groups often control diagnosis, referral, and the decision to intervene. Office-based BPH procedures, cystoscopy, urodynamics, bladder scanning, neuromodulation trials, injections, and catheter care are expanding. Vendors that provide patient marketing, reimbursement guidance, scheduling protocols, and staff training can accelerate adoption more effectively than vendors that focus only on device supply.
Academic medical centers and comprehensive cancer centers are early adopters of robotics, complex endourology, advanced imaging, ablation, and reconstructive technologies. They generate clinical evidence, train fellows, influence guidelines, and serve as regional referral hubs. Their purchasing standards are rigorous and often require peer-reviewed outcomes, research support, interoperability, and vendor commitment to education. Although their unit volume is smaller than the total community market, their influence on national adoption is disproportionate.
Home healthcare, long-term care, and rehabilitation providers represent a large but more price-sensitive market for catheters, drainage bags, intermittent catheter systems, bladder scanners, and continence-support products. Growth is supported by aging, home-based care, spinal cord injury, neurogenic bladder, and pressure to avoid catheter-associated complications. Product design must address patient independence, packaging, reimbursement, training, and supply continuity. Direct-to-patient services and specialty distribution are important commercial capabilities in this segment.

By Technology Type

Reusable endoscopic and capital platforms remain the largest technology type by installed value. They include endoscopy towers, reusable cystoscopes and ureteroscopes, lasers, shock-wave lithotripters, urodynamic systems, and robotic platforms. Their economics depend on utilization, maintenance, reprocessing, service, and staff competency. Large hospitals continue to prefer reusable systems where case volume is high and repair management is disciplined.
Single-use and procedure-specific disposable technologies are the fastest-growing technology type across endoscopy, access, drainage, and stone care. Disposable scopes, laser fibers, baskets, guidewires, stents, catheters, sheaths, and handpieces create predictable per-case cost and reduce asset-management complexity. The trade-off is waste generation and potentially higher unit cost, making health-economic analysis essential.
Laser, electrosurgical, and thermal energy technologies include holmium and thulium fiber lasers, bipolar resection, vaporization, radiofrequency, microwave, steam, and ablation systems. These technologies support stone fragmentation, prostate tissue removal, tumor resection, and hemostasis. Competitive differentiation is based on energy delivery, tissue effect, fiber durability, generator versatility, and compatibility with minimally invasive workflows.
Implantable and neuromodulation technologies include sacral neuromodulation systems, artificial urinary sphincters, prostate implants, slings, and selected temporary implants. These products command premium pricing and can create long-term follow-up relationships. Adoption depends on clinical durability, battery life, MRI compatibility, ease of programming, revision rates, and patient acceptance.
Robotic, image-guided, and software-enabled technologies are expected to record the highest value growth through 2035. They include multiport and single-port surgical robots, urology-specific robotic resection, AI-assisted ultrasound planning, digital surgical analytics, connected urodynamics, and remote monitoring. These platforms can improve consistency and data capture but require substantial capital, training, cybersecurity, and integration support.

Regional Insights: Where the Market is Growing Fastest

The U.S. Urology Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs based on population scale, age distribution, obesity and diabetes burden, kidney-stone prevalence, urologist density, hospital and ASC concentration, cancer-program strength, and willingness to adopt advanced capital systems. The South is the largest region, representing an estimated USD 1.82 billion in 2025. The West is the fastest-growing region, valued at approximately USD 1.07 billion in 2025. The Northeast accounted for an estimated USD 1.09 billion, while the Midwest represented USD 0.94 billion. By 2035, the South is projected to reach USD 3.64 billion, the West USD 2.19 billion, the Northeast USD 1.99 billion, and the Midwest USD 1.68 billion.

South

The South is the dominant regional market because it combines the largest population base with a high burden of diabetes, obesity, kidney stones, BPH, and urinary tract complications. The region includes Alabama, Arkansas, Delaware, the District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. It also contains many rapidly expanding metropolitan areas where health systems are adding ASCs, robotic operating rooms, endourology programs, and outpatient specialty capacity.

Texas is the largest urology device market in the South and one of the largest nationally. Houston, Dallas-Fort Worth, Austin, and San Antonio support major academic centers, cancer programs, integrated delivery networks, and high-volume community urology groups. The state has strong demand across stone management, prostate cancer surgery, BPH intervention, urinary drainage, and pelvic health. Its broad geography also creates a need for portable systems and single-use endoscopy in secondary cities and rural referral networks. Florida is the second major Southern market because of its large older-adult population. The state has strong Medicare exposure and high demand for BPH treatment, prostate and bladder cancer surveillance, incontinence therapy, catheter products, and outpatient procedures.

North Carolina, Georgia, Tennessee, Virginia, and Maryland are high-growth markets driven by population expansion, academic medical centers, and consolidation of regional health systems. North Carolina has strong research and cancer infrastructure in the Research Triangle and major referral programs in Charlotte and Winston-Salem. Georgia benefits from Atlanta-based health systems and a large statewide referral footprint. Tennessee has influential centers in Nashville, Memphis, and Knoxville, while Virginia and Maryland combine large suburban populations with advanced academic and federal healthcare networks. These states are attractive for robotic surgery, laser platforms, neuromodulation, and enterprise contracting.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia carry significant chronic disease and stone burden but face uneven specialist access. The Southeast has long been associated with a kidney-stone belt, supported by climate, hydration patterns, diet, and metabolic disease. In these states, large urban referral centers can support premium endourology and robotics, while rural areas require scalable drainage, diagnostic, and disposable solutions. South Carolina and Delaware are smaller by population but have growing older-adult and coastal communities that support BPH, continence, and cancer surveillance demand. The District of Columbia is a small market by volume but has high clinical acuity through academic and federal institutions.

The South is expected to reach approximately USD 3.64 billion by 2035, maintaining the largest regional share. Growth will be driven by ASCs, BPH procedure conversion, high stone volumes, prostate-cancer surgery, and expansion of health-system networks. Manufacturers will need differentiated strategies: enterprise capital and robotics for major systems, procedure-development support for large urology groups, and service-light disposable or portable products for underserved markets.

West

The West is expected to record the fastest regional growth through 2035. The region includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. It combines large innovation centers with fast-growing Sun Belt states and remote rural markets. The regional value is projected to rise from USD 1.07 billion in 2025 to approximately USD 2.19 billion in 2035, reflecting strong adoption of robotics, disposable endoscopy, digital platforms, and minimally invasive prostate and stone technologies.

California is the largest state market in the West and an important national launch environment. The state has a large population, leading academic centers, comprehensive cancer programs, major integrated systems, and a dense medtech ecosystem. It is influential in robotic surgery, AI-enabled systems, endoscopy, single-use devices, and value-based procurement. Large California systems can establish system-wide standards that materially affect vendor share. At the same time, labor and reprocessing costs can strengthen the economic case for single-use scopes and automated workflows.

Arizona, Nevada, Colorado, and Utah are high-growth markets. Arizona and Nevada are gaining older residents and expanding hospital capacity, supporting BPH, continence, stone, and oncology demand. Colorado and Utah have strong integrated delivery networks, advanced ambulatory infrastructure, and high adoption of minimally invasive surgery. Climate and hydration patterns also contribute to stone-disease demand in several Southwestern states. New Mexico has a smaller market but significant rural access needs, making portable diagnostics, disposable scopes, and hub-and-spoke referral models important.

Washington and Oregon have sophisticated provider systems and strong adoption of connected care, quality measurement, and system-level contracting. These markets are receptive to technologies that demonstrate lower reprocessing burden, improved patient experience, and defensible lifecycle economics. Idaho and Montana are growing but remain geographically dispersed, while Wyoming and Alaska have small populations and long travel distances to specialty care. Hawaii has concentrated demand around major islands and a meaningful older-adult population, creating opportunities for reliable equipment, remote support, and same-day outpatient pathways.

The West will gain market share because it aligns technology development with early clinical adoption. Manufacturers often use West Coast centers for clinical evaluation, surgeon education, and commercial reference sites. However, success requires navigating high labor costs, environmental scrutiny of disposable products, complex payer mixes, and strong evidence expectations. Products that combine premium performance with measurable workflow savings will be best positioned.

Northeast

The Northeast accounted for an estimated USD 1.09 billion in 2025 and remains one of the highest-value regions on a per-procedure basis. The region includes Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, and Pennsylvania. It has a dense concentration of academic hospitals, cancer centers, subspecialty urologists, and established referral networks. Growth is expected to be slower than in the West and South because population expansion is more limited, but premium technology adoption and procedure complexity support attractive revenue.

New York is the largest state market in the Northeast, supported by high population density, large hospital systems, and major academic programs in New York City, Long Island, Westchester, Albany, Rochester, and Buffalo. Demand is broad across bladder-cancer surveillance, robotic oncology, stone care, BPH, reconstruction, and pelvic health. Pennsylvania provides another large procedure base through Philadelphia, Pittsburgh, and statewide community networks. New Jersey benefits from dense suburban populations, proximity to major academic centers, and high utilization of outpatient specialty care.

Massachusetts is highly influential despite its smaller population. Boston-based academic centers are important for robotics, clinical trials, complex oncology, reconstructive urology, and technology evaluation. Connecticut and Rhode Island have mature hospital markets and strong access to regional referral networks. New Hampshire, Maine, and Vermont have older populations and rural geographies, creating demand for BPH, continence, cancer surveillance, and reliable drainage products, but specialist and capital access can be uneven outside major centers.

The Northeast is especially important for evidence-led procurement. Value-analysis committees often require comparative outcomes, infection-control data, and multi-year economic models before adopting new platforms. The region also has high labor and reprocessing costs, which can make single-use endoscopy economically attractive in selected workflows. Recent claims data showing high stone prevalence among older adults in the Northeast strengthen the case for investment in ureteroscopy, lasers, and stone evacuation.

By 2035, the Northeast is projected to reach approximately USD 1.99 billion. The most attractive opportunities will be advanced robotics, single-use endoscopy in high-cost settings, bladder-cancer surveillance, complex stone management, and continence programs. Commercial success will depend less on broad promotional reach and more on clinical evidence, contracting sophistication, and reference-center relationships.

Midwest

The Midwest represented an estimated USD 0.94 billion in 2025 and is expected to provide steady, durable growth through 2035. The region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota. Demand is supported by large community health systems, high chronic disease prevalence in several states, established cancer and transplant programs, and strong regional referral networks. The region is also important for medtech manufacturing, distribution, and clinical education.

Illinois, Ohio, Michigan, and Minnesota are the major state markets. Illinois benefits from Chicago’s concentration of academic centers, cancer programs, ASCs, and large health systems. Ohio has major urology and oncology capacity in Cleveland, Columbus, and Cincinnati, with a strong track record in robotic and minimally invasive surgery. Michigan supports large procedure volumes in Detroit, Grand Rapids, and statewide networks. Minnesota is strategically important because of its medical-device ecosystem and high concentration of clinical expertise, particularly in implantable technologies and health-system innovation.

Indiana, Wisconsin, Missouri, Iowa, and Kansas provide stable demand for stone management, BPH, continence, drainage, and robotic oncology. Indianapolis, Milwaukee, Madison, St. Louis, Kansas City, and Des Moines function as referral hubs for surrounding communities. Nebraska, North Dakota, and South Dakota are smaller markets but face substantial travel distances and specialist access constraints. These conditions support portable bladder scanning, disposable cystoscopy, tele-enabled support, and referral-center investment in efficient high-throughput platforms.

The Midwest is generally more price-sensitive than the Northeast or coastal West, but providers value reliability, service coverage, and clinical education. Manufacturers often win through long-term relationships, regional contracting, equipment standardization, and strong field support. Capital purchases must demonstrate a clear utilization pathway and frequently require cross-facility or cross-specialty use. Products that reduce repeat procedures or improve outpatient throughput can justify premium pricing even in cost-conscious systems.

The Midwest market is projected to reach approximately USD 1.68 billion by 2035. Growth will be led by replacement of aging endoscopy and laser equipment, continued robotic surgery adoption, expansion of ASC-based stone and BPH care, and greater use of connected diagnostics. The region will remain a dependable market for mature categories while selectively adopting technologies with strong clinical and economic evidence.

Key Market Players

The U.S. Urology Devices Competitive Landscape is moderately consolidated in capital equipment, robotics, neuromodulation, and endoscopy, but fragmented across catheters, stone consumables, drainage, diagnostics, and emerging BPH technologies. Large global medtech companies compete through broad portfolios, enterprise contracting, service infrastructure, and physician training. Specialized companies can still gain share by solving a specific clinical or workflow problem, particularly in BPH, stone evacuation, urethral stricture, single-use endoscopy, and pelvic health.

Competition is increasingly platform-based. A stone-management vendor may combine scopes, lasers, fibers, baskets, sheaths, stents, and service. A BPH vendor may provide capital, single-use handpieces, ultrasound integration, training, patient identification, and reimbursement support. A continence company may combine neuromodulation, bulking, and patient-management infrastructure. This platform approach increases switching costs and allows suppliers to negotiate across multiple sites of care.

Some of the key players in the U.S. Urology Devices industry are

Boston Scientific Corporation
Olympus Corporation
KARL STORZ SE & Co. KG
Cook Medical
Coloplast A/S
Becton, Dickinson and Company
Teleflex Incorporated
Medtronic plc
Intuitive Surgical, Inc.
PROCEPT BioRobotics Corporation
Ambu A/S
Richard Wolf GmbH
Dornier MedTech
Quanta System S.p.A.
EDAP TMS S.A.
Laborie Medical Technologies
Stryker Corporation
B. Braun Melsungen AG
Convatec Group Plc
Hollister Incorporated
Urotronic, Inc.
Zenflow, Inc.
Palette Life Sciences
Caldera Medical
Nipro Corporation

Boston Scientific, Olympus, KARL STORZ, Cook Medical, Coloplast, BD, and Teleflex hold broad positions across endourology, stone management, drainage, BPH, and pelvic health. Boston Scientific strengthened its continence portfolio through the completed acquisition of Axonics, adding sacral neuromodulation and urethral bulking to an established urology franchise. Olympus and KARL STORZ remain influential in reusable endoscopy and visualization, while Ambu and other disposable-scope suppliers are reshaping the cystoscopy and ureteroscopy economics. Cook Medical, BD, Coloplast, Convatec, Hollister, B. Braun, and Nipro compete heavily in access, drainage, catheters, stents, and recurring consumables.

Intuitive Surgical remains the leading robotic-surgery platform provider, while Medtronic is entering the U.S. urologic robotic market with Hugo. PROCEPT BioRobotics is building a dedicated urology robotics category around Aquablation. Dornier, Quanta System, EDAP TMS, and other energy-platform companies compete in laser lithotripsy, shock-wave therapy, and tissue ablation. Laborie is important in urodynamics and pelvic health, while Urotronic, Zenflow, Palette Life Sciences, and Caldera Medical represent specialized innovators in stricture, BPH, bulking, and continence solutions.

Market share through 2035 will be influenced by FDA clearances, clinical durability, surgeon training capacity, ASC compatibility, service reliability, and the ability to prove total procedural value. Supply-chain resilience will remain important because many urology procedures depend on small, specialized consumables. Companies that can reduce procedure time, reprocessing cost, catheter duration, retreatment, or unplanned utilization will have the strongest defense against price compression.

Recent Developments

Recent developments in the U.S. Urology Devices Market show a clear shift toward robotics, disposable endoscopy, and portfolio consolidation. In March 2024, Intuitive Surgical received FDA clearance for the da Vinci 5 system, introducing a new capital replacement cycle for hospitals with high robotic utilization. The platform is relevant to radical prostatectomy, partial nephrectomy, cystectomy, and reconstructive urology, and it increases competitive pressure on hospitals to evaluate fleet capacity, instrument economics, and data-enabled workflow tools.

In April 2024, Olympus announced FDA clearance of the RenaFlex single-use flexible ureteroscope. The launch reinforced the hybrid endoscopy model in which providers can choose between reusable and disposable scopes based on case volume, repair history, infection-control requirements, and site of care. Disposable ureteroscopy is expected to expand fastest in ASCs, emergency coverage, satellite hospitals, and complex cases where guaranteed scope performance has a high operational value.

In August 2024, PROCEPT BioRobotics received FDA clearance for the HYDROS robotic system for Aquablation therapy. The platform added AI-assisted treatment planning, integrated ultrasound and cystoscopic visualization, robotic waterjet resection, and a streamlined footprint. The development is strategically important because it moves BPH treatment toward image-guided, standardized tissue removal and strengthens the case for dedicated urology capital systems with recurring handpiece revenue.

In November 2024, Boston Scientific completed its acquisition of Axonics. The transaction expanded Boston Scientific into sacral neuromodulation and strengthened its position in urinary and bowel dysfunction. The combination creates opportunities for broader contracting across BPH, stone management, pelvic health, and continence. It also raises the competitive bar for Medtronic and smaller pelvic-health companies because large urology groups increasingly prefer vendors that can support multiple treatment pathways.

In December 2025, Medtronic received FDA clearance for the Hugo robotic-assisted surgery system for urologic procedures, and the first U.S. commercial case was announced in early 2026. This introduces a meaningful second large-company alternative in a market historically dominated by Intuitive Surgical. Adoption will depend on clinical performance, training, instrument availability, capital structure, room integration, and the ability to scale service across U.S. health systems.

The reimbursement and site-of-care environment also continued to evolve. Medicare-certified ASCs increased to 6,436 in 2024, and CMS maintained annual updates to the outpatient and ASC payment systems. This supports continued migration of appropriate urology procedures to lower-cost settings, while increasing scrutiny of quality, unplanned hospital visits, and patient selection. Manufacturers must therefore support both procedural efficiency and measurable safety outcomes.

Conclusion

The U.S. Urology Devices Market Size & Share is positioned for sustained expansion from USD 4.92 billion in 2025 to USD 9.50 billion by 2035, supported by a 6.80% CAGR during the forecast period. The market’s long-term strength is grounded in population aging, high prevalence of BPH, urinary incontinence, kidney stones, and urologic cancers, as well as the recurring nature of diagnosis, surveillance, intervention, and follow-up. Unlike a single-procedure market, urology combines stable commodity demand with premium capital and implantable-device growth.

The most attractive growth opportunities will come from single-use endoscopy, high-efficiency laser lithotripsy, active stone evacuation, robotic waterjet BPH treatment, office and ASC-based prostate procedures, sacral neuromodulation, robotic oncology surgery, digital urodynamics, and software-assisted procedural planning. Mature categories such as catheters, stents, reusable cystoscopes, retrieval devices, and transurethral instruments will remain important, but value growth will concentrate in technologies that improve throughput, reduce reprocessing, shorten recovery, and expand treatment eligibility.

Regional opportunity will be led by the South due to population scale, chronic disease burden, and rapid provider expansion. The West will grow fastest because of innovation adoption, population growth, and high labor-cost pressure that favors workflow automation. The Northeast will remain a premium evidence-driven market with strong academic and cancer programs. The Midwest will provide stable demand and reward vendors with service reliability, clinical education, and credible economic value. At the state level, California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, New Jersey, Massachusetts, North Carolina, Georgia, Arizona, Michigan, and Minnesota will be particularly important for national commercialization.

For clients evaluating this market, the central question is not whether urology procedure demand will increase. The more important questions are which procedures will move to ASCs and offices, which capital platforms will generate defensible recurring revenue, how single-use and reusable economics will be balanced, and which companies can convert clinical innovation into provider-level financial value. Manufacturers that combine differentiated technology with reimbursement support, workflow redesign, training, supply reliability, and real-world evidence will define the next decade of the U.S. urology devices industry.

TABLE OF CONTENT

1. U.S. Urology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Urology Device Manufacturers
1.6.2. Component, Materials, and Contract Manufacturing Suppliers
1.6.3. Hospitals and Integrated Delivery Networks
1.6.4. Urology Practices and Specialty Care Centers
1.6.5. Ambulatory Surgery Centers and Outpatient Procedure Facilities
1.6.6. Group Purchasing Organizations, Distributors, and Specialty Suppliers
1.6.7. Payers, Regulators, Urologists, and Clinical Decision-Makers

What this section provides: This section defines the market boundary, study scope, methodology, assumptions, product inclusion criteria, and stakeholder ecosystem so clients understand how the U.S. urology devices market is measured, segmented, and validated.

2. U.S. Urology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.7.1. Single-Use Ureteroscopy and Cystoscopy
2.7.2. Advanced Laser Lithotripsy Platforms
2.7.3. Minimally Invasive BPH Treatment Devices
2.7.4. Sacral Neuromodulation and Continence Technologies
2.7.5. Robotic and Image-Guided Urologic Surgery
2.7.6. Connected Urodynamics and Home-Based Urinary Care

What this section provides: This section gives decision-makers a concise view of market size, growth direction, leading product categories, major clinical demand pockets, competitive intensity, and priority investment opportunities.

3. U.S. Urology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Prevalence of Kidney Stones and Recurrent Urolithiasis
3.1.2. Aging Population and Increasing Benign Prostatic Hyperplasia Burden
3.1.3. Growth in Urinary Incontinence and Neurogenic Bladder Management
3.1.4. Expansion of Minimally Invasive and Endoscopic Urology Procedures
3.1.5. Increasing Urologic Cancer Diagnosis and Surgical Intervention
3.1.6. Migration of Urology Procedures to Ambulatory Settings
3.1.7. Hospital Investment in Robotic Surgery and Laser Platforms
3.1.8. Growing Demand for Home-Based Catheterization and Continence Care

3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Robotic, Laser, and Imaging Systems
3.2.2. Reimbursement Pressure and Value Analysis Scrutiny
3.2.3. Catheter-Associated Infection and Device Safety Concerns
3.2.4. Product Recalls, Sterilization Risk, and Regulatory Compliance Costs
3.2.5. Urologist and Specialized Nursing Workforce Constraints
3.2.6. Pricing Pressure in Mature Catheter and Consumable Categories

3.3. Opportunities and Their Impact Analysis
3.3.1. Single-Use Urology Endoscope Adoption
3.3.2. Thulium Fiber and High-Power Holmium Laser Expansion
3.3.3. Minimally Invasive Surgical Therapies for BPH
3.3.4. Robotic-Assisted Prostate, Kidney, and Reconstructive Surgery
3.3.5. Sacral Neuromodulation and Implantable Continence Solutions
3.3.6. Outpatient Stone Management and Same-Day Urology Procedures
3.3.7. AI-Assisted Imaging, Diagnostics, and Procedure Planning
3.3.8. Remote Monitoring and Connected Bladder Management

3.4. Challenges and Their Impact Analysis
3.4.1. Clinical Evidence Requirements for Premium Device Adoption
3.4.2. Hospital Capital Budget Competition
3.4.3. Reprocessing Complexity and Infection-Control Requirements
3.4.4. Physician Training and Learning-Curve Barriers
3.4.5. Rural Urology Access and Referral Network Limitations

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Hospital Capital Procurement Behavior Analysis
3.8. Procedure Migration and Site-of-Care Analysis
3.9. Urology Device Replacement-Cycle Analysis

What this section provides: This section explains the clinical, commercial, reimbursement, technological, and operational forces shaping Urology Devices demand, enabling clients to evaluate growth opportunities, adoption barriers, and execution risks.

4. U.S. Urology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization and Connected Urology
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Premarket Notification and 510(k) Pathways
4.7.2. Premarket Approval Requirements
4.7.3. De Novo Classification Pathway
4.7.4. Quality System and Post-Market Surveillance Requirements
4.7.5. Single-Use and Reprocessed Device Regulation

4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Inpatient Prospective Payment Considerations
4.8.2. Hospital Outpatient Reimbursement
4.8.3. Ambulatory Surgical Center Reimbursement
4.8.4. Physician Fee Schedule Considerations
4.8.5. Durable Medical Equipment and Homecare Coverage

4.9. Import/Export Restrictions & Tariff Impact
4.10. Government Initiatives and Public Health Programs
4.11. Impact of Escalating Geopolitical Tensions
4.12. Hospital Value Analysis Committee Decision Framework
4.13. Infection Prevention and Endoscope Reprocessing Requirements
4.14. Cybersecurity and Connected Device Compliance

What this section provides: This section gives clients a complete view of the external market environment, including regulation, reimbursement, pricing, supply chain, infection control, digital technology adoption, and hospital procurement dynamics.

5. U.S. Urology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Urology Endoscopes and Visualization Systems
5.1.2.1. Cystoscopes
5.1.2.2. Ureteroscopes
5.1.2.3. Nephroscopes
5.1.2.4. Resectoscopes
5.1.2.5. Laparoscopes Used in Urology
5.1.2.6. Reusable Urology Endoscopes
5.1.2.7. Single-Use Urology Endoscopes
5.1.2.8. Camera Heads, Light Sources, and Video Processors

5.1.3. Urinary Catheters and Drainage Products
5.1.3.1. Intermittent Catheters
5.1.3.2. Indwelling Foley Catheters
5.1.3.3. External Urinary Catheters
5.1.3.4. Suprapubic Catheters
5.1.3.5. Nephrostomy Catheters
5.1.3.6. Ureteral Catheters
5.1.3.7. Urinary Drainage Bags and Accessories
5.1.3.8. Hydrophilic and Antimicrobial Catheters

5.1.4. Kidney Stone Management Devices
5.1.4.1. Laser Lithotripsy Systems
5.1.4.2. Intracorporeal Lithotripters
5.1.4.3. Extracorporeal Shock Wave Lithotripsy Systems
5.1.4.4. Stone Retrieval Baskets
5.1.4.5. Guidewires and Access Sheaths
5.1.4.6. Ureteral Stents
5.1.4.7. Stone Fragmentation and Suction Systems
5.1.4.8. Percutaneous Nephrolithotomy Instruments

5.1.5. BPH and Prostate Treatment Devices
5.1.5.1. Transurethral Resection Systems
5.1.5.2. Laser Enucleation and Vaporization Systems
5.1.5.3. Prostatic Urethral Lift Devices
5.1.5.4. Water Vapor Thermal Therapy Devices
5.1.5.5. Robotic Waterjet Ablation Systems
5.1.5.6. Temporary Implantable Prostatic Devices
5.1.5.7. Prostate Biopsy and Localization Devices
5.1.5.8. High-Intensity Focused Ultrasound Systems

5.1.6. Urinary Incontinence, Pelvic Floor, and Urodynamic Devices
5.1.6.1. Male Slings
5.1.6.2. Female Slings
5.1.6.3. Artificial Urinary Sphincters
5.1.6.4. Sacral Neuromodulation Systems
5.1.6.5. Tibial Nerve Stimulation Devices
5.1.6.6. Urodynamic Systems
5.1.6.7. Bladder Scanners
5.1.6.8. Pelvic Floor Stimulation and Rehabilitation Devices

What this section provides: This section identifies the Urology Devices categories expected to generate the largest revenue contribution, strongest recurring consumable demand, and fastest technology-led growth through 2035.

6. U.S. Urology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)

6.1.2. Urolithiasis and Kidney Stone Management
6.1.2.1. Renal Stones
6.1.2.2. Ureteral Stones
6.1.2.3. Bladder Stones
6.1.2.4. Recurrent Stone Disease
6.1.2.5. Complex and Large Stone Burden

6.1.3. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms
6.1.3.1. Mild-to-Moderate BPH
6.1.3.2. Moderate-to-Severe BPH
6.1.3.3. Medication-Refractory BPH
6.1.3.4. Urinary Retention Associated with BPH
6.1.3.5. Large Prostate Treatment

6.1.4. Urinary Incontinence and Urinary Retention
6.1.4.1. Stress Urinary Incontinence
6.1.4.2. Urge Urinary Incontinence
6.1.4.3. Mixed Urinary Incontinence
6.1.4.4. Overflow Incontinence
6.1.4.5. Post-Prostatectomy Incontinence
6.1.4.6. Chronic Urinary Retention

6.1.5. Urologic Cancer Diagnosis and Treatment
6.1.5.1. Prostate Cancer
6.1.5.2. Bladder Cancer
6.1.5.3. Kidney Cancer
6.1.5.4. Ureteral and Upper Tract Urothelial Cancer
6.1.5.5. Testicular and Penile Cancer
6.1.5.6. Cancer Biopsy, Localization, and Surveillance

6.1.6. Neuro-Urology and Reconstructive Urology
6.1.6.1. Neurogenic Bladder
6.1.6.2. Overactive Bladder
6.1.6.3. Urethral Stricture
6.1.6.4. Urinary Diversion and Reconstruction
6.1.6.5. Vesicoureteral Reflux
6.1.6.6. Congenital and Pediatric Urologic Conditions

What this section provides: This section explains demand by clinical indication and enables clients to prioritize applications with strong patient volumes, procedure growth, reimbursement relevance, and unmet device needs.

7. U.S. Urology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)

7.1.2. Hospitals and Integrated Health Systems
7.1.2.1. Academic Medical Centers
7.1.2.2. Community Hospitals
7.1.2.3. Regional Referral Hospitals
7.1.2.4. Veterans Affairs and Government Hospitals

7.1.3. Ambulatory Surgery Centers and Outpatient Procedure Facilities
7.1.3.1. Independent Ambulatory Surgery Centers
7.1.3.2. Hospital-Owned Ambulatory Surgery Centers
7.1.3.3. Urology-Focused Procedure Centers
7.1.3.4. Office-Based Surgical Facilities

7.1.4. Urology Clinics and Specialty Care Centers
7.1.4.1. Independent Urology Practices
7.1.4.2. Multispecialty Physician Groups
7.1.4.3. Prostate and BPH Treatment Centers
7.1.4.4. Continence and Pelvic Health Centers
7.1.4.5. Stone Disease Clinics

7.1.5. Diagnostic and Urologic Testing Centers
7.1.5.1. Urodynamic Testing Centers
7.1.5.2. Imaging and Diagnostic Centers
7.1.5.3. Prostate Biopsy Centers
7.1.5.4. Cancer Surveillance Facilities

7.1.6. Home Healthcare and Long-Term Care Providers
7.1.6.1. Home Catheterization Providers
7.1.6.2. Skilled Nursing Facilities
7.1.6.3. Rehabilitation Centers
7.1.6.4. Assisted Living Facilities
7.1.6.5. Veterans and Community Homecare Programs

What this section provides: This section explains which care settings and customer groups drive Urology Devices purchasing, procedure adoption, capital-equipment investment, and recurring catheter, drainage, and continence-product demand.

8. U.S. Urology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)

8.1.2. Endoscopic and Visualization Technologies
8.1.2.1. Flexible Endoscopy
8.1.2.2. Rigid Endoscopy
8.1.2.3. Digital Endoscopy
8.1.2.4. Fiberoptic Endoscopy
8.1.2.5. High-Definition and 4K Visualization
8.1.2.6. Single-Use Endoscopic Platforms

8.1.3. Laser and Energy-Based Technologies
8.1.3.1. Holmium Lasers
8.1.3.2. Thulium Fiber Lasers
8.1.3.3. Thulium Lasers
8.1.3.4. Bipolar and Monopolar Electrosurgery
8.1.3.5. Radiofrequency and Thermal Technologies
8.1.3.6. High-Intensity Focused Ultrasound

8.1.4. Robotic, Navigation, and Image-Guided Technologies
8.1.4.1. Robotic-Assisted Surgical Systems
8.1.4.2. Robotic BPH Treatment Systems
8.1.4.3. MRI-Ultrasound Fusion Biopsy Systems
8.1.4.4. Fluoroscopy and Ultrasound Guidance
8.1.4.5. Electromagnetic Navigation
8.1.4.6. AI-Assisted Procedure Planning

8.1.5. Implantable and Neuromodulation Technologies
8.1.5.1. Sacral Neuromodulation Implants
8.1.5.2. Artificial Urinary Sphincters
8.1.5.3. Urethral and Pelvic Slings
8.1.5.4. Prostatic Implants
8.1.5.5. Ureteral Stents
8.1.5.6. Implantable Continence Devices

8.1.6. Single-Use, Digital, and Connected Technologies
8.1.6.1. Single-Use Cystoscopes
8.1.6.2. Single-Use Ureteroscopes
8.1.6.3. Digital Urodynamic Systems
8.1.6.4. Connected Bladder Scanners
8.1.6.5. Remote Neuromodulation Programming
8.1.6.6. Home Catheterization Management Platforms
8.1.6.7. Software-Enabled Urology Workflow Solutions

What this section provides: This section evaluates the technology platforms shaping contemporary urology care, including endoscopy, laser treatment, robotics, image guidance, implantable therapy, single-use devices, and digitally connected workflows.

9. U.S. Urology Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)

9.1.2. Direct Hospital and Health System Procurement
9.1.2.1. Capital Equipment Contracts
9.1.2.2. Consumable Supply Agreements
9.1.2.3. Service and Maintenance Contracts
9.1.2.4. Procedure-Based Purchasing Agreements

9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.3.1. Multi-Hospital Standardization
9.1.3.2. Enterprise Endoscopy Contracts
9.1.3.3. Robotic Platform Agreements
9.1.3.4. System-Wide Catheter Standardization

9.1.4. Group Purchasing Organization Contracts
9.1.4.1. National GPO Agreements
9.1.4.2. Regional GPO Agreements
9.1.4.3. Aggregated Consumable Purchasing
9.1.4.4. Committed-Volume Contracts

9.1.5. Distributor and Specialty Supplier Sales
9.1.5.1. National Medical-Surgical Distributors
9.1.5.2. Regional Urology Distributors
9.1.5.3. Durable Medical Equipment Suppliers
9.1.5.4. Homecare Catheter Suppliers

9.1.6. Ambulatory, Physician-Office, and Homecare Procurement
9.1.6.1. Ambulatory Surgery Center Purchasing
9.1.6.2. Independent Urology Practice Purchasing
9.1.6.3. Office-Based Procedure Procurement
9.1.6.4. Direct-to-Patient Catheter Fulfilment
9.1.6.5. E-Commerce and Subscription-Based Supply Models

What this section provides: This section explains how Urology Devices are purchased in the United States, including hospital contracting, IDN standardization, GPO influence, distributor relationships, outpatient purchasing, and direct-to-patient supply models.

10. U.S. Urology Devices Market – By Geography
10.1. Introduction

10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Urology Procedure Volume and Hospital Infrastructure Analysis
10.1.4. Regional Urologist Density and Referral Network Analysis
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional Ambulatory Procedure Migration Analysis
10.1.7. Regional Disease Burden and Aging Population Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Urology Device Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Urology Device Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Urology Device Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.24. District of Columbia

10.4.24.1. Overview
10.4.24.2. District of Columbia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.24.3. District of Columbia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.24.4. District of Columbia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.24.5. District of Columbia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.24.6. District of Columbia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Urology Device Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis, enabling clients to identify priority U.S. geographies, urology procedure-volume hubs, older-adult demand centers, outpatient adoption hotspots, underserved territories, and state-level commercial opportunities.

11. U.S. Urology Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players

11.3. Company Profiles
11.3.1. Boston Scientific Corporation
11.3.2. Olympus Corporation
11.3.3. Coloplast A/S
11.3.4. Becton, Dickinson and Company
11.3.5. Teleflex Incorporated
11.3.6. Medtronic plc
11.3.7. Intuitive Surgical, Inc.
11.3.8. KARL STORZ SE & Co. KG
11.3.9. Cook Medical
11.3.10. Stryker Corporation
11.3.11. Johnson & Johnson MedTech
11.3.12. Richard Wolf GmbH
11.3.13. Dornier MedTech
11.3.14. Lumenis Be Ltd.
11.3.15. Ambu A/S
11.3.16. Laborie Medical Technologies
11.3.17. PROCEPT BioRobotics Corporation
11.3.18. EDAP TMS S.A.
11.3.19. Hollister Incorporated
11.3.20. Convatec Group Plc
11.3.21. Wellspect HealthCare
11.3.22. Verathon Inc.
11.3.23. Quanta System S.p.A.
11.3.24. Sonablate Corp.
11.3.25. Urotronic, Inc.

11.4. Competitive Benchmarking by Product Category
11.5. Competitive Benchmarking by Clinical Application
11.6. U.S. Distribution and Service-Network Comparison
11.7. Product Launch and FDA Clearance Tracker
11.8. Merger, Acquisition, Partnership, and Licensing Analysis
11.9. Clinical Trial and Evidence-Generation Benchmarking

Note: Each company profile will include company overview, Urology Devices portfolio, U.S. market strategy, financial positioning, clinical pipeline, FDA and regulatory updates, partnerships, acquisitions, product launches, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, innovation direction, regulatory progress, and strategic intelligence on leading Urology Devices companies.

12. U.S. Urology Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Disruptive Technologies Impact
12.2.1. Single-Use Ureteroscopy and Cystoscopy
12.2.2. Thulium Fiber Laser Lithotripsy
12.2.3. Robotic BPH Treatment Platforms
12.2.4. Robotic-Assisted Urologic Surgery
12.2.5. AI-Assisted Prostate Imaging and Biopsy
12.2.6. Implantable Sacral Neuromodulation
12.2.7. Connected Urodynamics and Bladder Monitoring
12.2.8. Miniaturized Percutaneous Stone Surgery
12.2.9. Drug-Coated and Implantable Urology Devices

12.3. Emerging Business Trends
12.3.1. Shift Toward Procedure-Ecosystem Contracting
12.3.2. Growth of Urology-Focused Ambulatory Surgery Centers
12.3.3. Expansion of Direct-to-Patient Catheter Supply
12.3.4. Recurring Revenue from Disposable and Single-Use Devices
12.3.5. Service-Based Capital Equipment Models
12.3.6. Vendor Consolidation Across Urology Service Lines

12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Product White-Space Analysis
12.7. Future Hospital Procurement Model
12.8. Expected Changes in Site of Care Through 2035

What this section provides: This section prepares clients for future technology shifts, care-delivery changes, market-structure evolution, investment opportunities, and potential adoption scenarios through 2035.

13. U.S. Urology Devices Market: Strategic Recommendations

13.1. Recommendations for Urology Device Manufacturers
13.2. Recommendations for Hospitals and Integrated Health Systems
13.3. Recommendations for Urology Practices and Ambulatory Surgery Centers
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Distributors and Channel Partners
13.6. Recommendations for New Entrants and Startups
13.7. Go-to-Market Strategy Considerations
13.8. Product Positioning and Portfolio Expansion Guidance
13.9. Clinical Evidence and Reimbursement Strategy
13.10. State-Level Commercial Prioritization
13.11. Physician Training and Key Opinion Leader Strategy
13.12. Service, Maintenance, and Customer-Support Strategy
13.13. Acquisition and Partnership Opportunity Framework

What this section provides: This section converts U.S. urology market intelligence into actionable strategy for growth planning, product positioning, channel expansion, clinical evidence generation, investment decisions, and competitive differentiation.

14. U.S. Urology Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Regulatory and Reimbursement Disclaimer
14.7. Company and Product Information Disclaimer

What this section provides: This section clarifies the report’s limitations, legal boundaries, data-use terms, forecasting assumptions, and treatment of third-party, regulatory, reimbursement, company, and product information.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Urology Devices Market: Market Definition and Scope
TABLE 3: U.S. Urology Devices Market: Research Methodology Framework
TABLE 4: U.S. Urology Devices Market: Key Assumptions
TABLE 5: U.S. Urology Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Urology Devices Market: Stakeholder Analysis
TABLE 7: U.S. Urology Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Urology Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Urology Devices Market: Market Attractiveness Index
TABLE 10: U.S. Urology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Urology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Urology Devices Market: High-Growth Opportunity Areas, 2026–2035
TABLE 13: U.S. Urology Devices Market: Drivers and Impact Analysis
TABLE 14: U.S. Urology Devices Market: Restraints and Impact Analysis
TABLE 15: U.S. Urology Devices Market: Opportunities and Impact Analysis
TABLE 16: U.S. Urology Devices Market: Challenges and Impact Analysis
TABLE 17: U.S. Urology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. Urology Devices Market: Clinical Workflow Economics Matrix
TABLE 19: U.S. Urology Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 20: U.S. Urology Devices Market: Procedure Migration and Site-of-Care Analysis
TABLE 21: U.S. Urology Devices Market: Device Replacement-Cycle Analysis
TABLE 22: U.S. Urology Devices Market: PESTEL Analysis
TABLE 23: U.S. Urology Devices Market: Porter’s Five Forces Analysis
TABLE 24: U.S. Urology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 25: U.S. Urology Devices Market: Value Chain Analysis
TABLE 26: U.S. Urology Devices Market: Supply Chain Analysis
TABLE 27: U.S. Urology Devices Market: Digitalization and Connected Urology Impact
TABLE 28: U.S. Urology Devices Market: Application & Innovation Landscape
TABLE 29: U.S. Urology Devices Market: FDA Regulatory Framework Analysis
TABLE 30: U.S. Urology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 31: U.S. Urology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 32: U.S. Urology Devices Market: Government Initiatives and Public Health Programs
TABLE 33: U.S. Urology Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 34: U.S. Urology Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 35: U.S. Urology Devices Market: Infection Prevention and Endoscope Reprocessing Requirements
TABLE 36: U.S. Urology Devices Market: Connected Device Cybersecurity and Compliance Analysis
TABLE 37: U.S. Urology Devices Market: Product Category Snapshot, 2025
TABLE 38: Segment Dashboard; Definition and Scope, by Product Category
TABLE 39: U.S. Urology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 40: U.S. Urology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 41: Urology Endoscopes and Visualization Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: Urinary Catheters and Drainage Products Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: Kidney Stone Management Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: BPH and Prostate Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Urinary Incontinence, Pelvic Floor, and Urodynamic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Urology Devices Market: Application Snapshot, 2025
TABLE 47: Segment Dashboard; Definition and Scope, by Application
TABLE 48: U.S. Urology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 49: U.S. Urology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 50: Urolithiasis and Kidney Stone Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Urinary Incontinence and Urinary Retention Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Urologic Cancer Diagnosis and Treatment Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Neuro-Urology and Reconstructive Urology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Urology Devices Market: End User Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by End User
TABLE 57: U.S. Urology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 58: U.S. Urology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 59: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: Ambulatory Surgery Centers and Outpatient Procedure Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Urology Clinics and Specialty Care Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Diagnostic and Urologic Testing Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Home Healthcare and Long-Term Care Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Urology Devices Market: Technology Type Snapshot, 2025
TABLE 65: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 66: U.S. Urology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 67: U.S. Urology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 68: Endoscopic and Visualization Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Laser and Energy-Based Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: Robotic, Navigation, and Image-Guided Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Implantable and Neuromodulation Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: Single-Use, Digital, and Connected Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Urology Devices Market: Procurement Channel Snapshot, 2025
TABLE 74: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 75: U.S. Urology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 76: U.S. Urology Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 77: Direct Hospital and Health System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: Distributor and Specialty Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: Ambulatory, Physician-Office, and Homecare Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Urology Devices Market: Regional Snapshot, 2025
TABLE 83: Segment Dashboard; Definition and Scope, by Geography
TABLE 84: U.S. Urology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 85: U.S. Urology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 86: U.S. Urology Devices Market: Regional Procedure Volume and Hospital Infrastructure Analysis
TABLE 87: U.S. Urology Devices Market: Regional Reimbursement and Procurement Dynamics
TABLE 88: West Region U.S. Urology Devices Market: Regional Overview and Trends
TABLE 89: West Region U.S. Urology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 90: West Region U.S. Urology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 91: West Region U.S. Urology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Urology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Urology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Urology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Urology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 96: California Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 97: Washington Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 98: Arizona Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 99: Colorado Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 100: Oregon Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 101: Utah Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 102: Nevada Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 103: New Mexico Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 104: Idaho Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 105: Montana Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 106: Wyoming Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 107: Alaska Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 108: Hawaii Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region U.S. Urology Devices Market: Regional Overview and Trends
TABLE 110: Northeast Region U.S. Urology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 111: Northeast Region U.S. Urology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Urology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Urology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. Urology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Urology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 116: Northeast Region U.S. Urology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 117: New York Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 118: Massachusetts Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 119: New Jersey Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 120: Pennsylvania Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 121: Connecticut Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 122: Maine Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 123: Vermont Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 124: New Hampshire Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 125: Rhode Island Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 126: Delaware Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 127: South Region U.S. Urology Devices Market: Regional Overview and Trends
TABLE 128: South Region U.S. Urology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 129: South Region U.S. Urology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 130: South Region U.S. Urology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. Urology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Urology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: South Region U.S. Urology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 134: South Region U.S. Urology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 135: Texas Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 136: Florida Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 137: Georgia Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 138: North Carolina Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 139: Tennessee Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 140: South Carolina Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 141: Alabama Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 142: Mississippi Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 143: Louisiana Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 144: Arkansas Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 145: Kentucky Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 146: Oklahoma Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 147: Virginia Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 148: Maryland Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 149: West Virginia Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 150: District of Columbia Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 151: Midwest Region U.S. Urology Devices Market: Regional Overview and Trends
TABLE 152: Midwest Region U.S. Urology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 153: Midwest Region U.S. Urology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. Urology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 155: Midwest Region U.S. Urology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 156: Midwest Region U.S. Urology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 157: Midwest Region U.S. Urology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 158: Midwest Region U.S. Urology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 159: Illinois Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 160: Ohio Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 161: Michigan Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 162: Minnesota Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 163: Indiana Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 164: Wisconsin Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 165: Missouri Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 166: Iowa Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 167: Kansas Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 168: Nebraska Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 169: North Dakota Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 170: South Dakota Urology Devices Market: Market Size and Forecast by Key Segment, 2021–2035 (US$ Billion)
TABLE 171: U.S. Urology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 172: U.S. Urology Devices Market: Key Company Market Share Analysis, 2025
TABLE 173: U.S. Urology Devices Market: Company Positioning Matrix
TABLE 174: U.S. Urology Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 175: U.S. Urology Devices Market: Competitive Benchmarking by Product Category
TABLE 176: U.S. Urology Devices Market: Competitive Benchmarking by Clinical Application
TABLE 177: U.S. Urology Devices Market: Distribution and Service-Network Comparison
TABLE 178: U.S. Urology Devices Market: Product Launch and FDA Clearance Tracker
TABLE 179: U.S. Urology Devices Market: Strategic Developments, Partnerships, M&A and Licensing Analysis
TABLE 180: Boston Scientific Corporation: Company Profile
TABLE 181: Olympus Corporation: Company Profile
TABLE 182: Coloplast A/S: Company Profile
TABLE 183: Becton, Dickinson and Company: Company Profile
TABLE 184: Teleflex Incorporated: Company Profile
TABLE 185: Medtronic plc: Company Profile
TABLE 186: Intuitive Surgical, Inc.: Company Profile
TABLE 187: KARL STORZ SE & Co. KG: Company Profile
TABLE 188: Cook Medical: Company Profile
TABLE 189: Stryker Corporation: Company Profile
TABLE 190: Johnson & Johnson MedTech: Company Profile
TABLE 191: Richard Wolf GmbH: Company Profile
TABLE 192: Dornier MedTech: Company Profile
TABLE 193: Lumenis Be Ltd.: Company Profile
TABLE 194: Ambu A/S: Company Profile
TABLE 195: Laborie Medical Technologies: Company Profile
TABLE 196: PROCEPT BioRobotics Corporation: Company Profile
TABLE 197: EDAP TMS S.A.: Company Profile
TABLE 198: Hollister Incorporated: Company Profile
TABLE 199: Convatec Group Plc: Company Profile
TABLE 200: Wellspect HealthCare: Company Profile
TABLE 201: Verathon Inc.: Company Profile
TABLE 202: Quanta System S.p.A.: Company Profile
TABLE 203: Sonablate Corp.: Company Profile
TABLE 204: Urotronic, Inc.: Company Profile
TABLE 205: U.S. Urology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 206: U.S. Urology Devices Market: Disruptive Technologies Impact Matrix
TABLE 207: U.S. Urology Devices Market: Emerging Business Trends
TABLE 208: U.S. Urology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 209: U.S. Urology Devices Market: Investment Prioritization Matrix
TABLE 210: U.S. Urology Devices Market: Product White-Space Analysis
TABLE 211: U.S. Urology Devices Market: Future Hospital Procurement Model
TABLE 212: U.S. Urology Devices Market: Expected Site-of-Care Changes Through 2035
TABLE 213: U.S. Urology Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 214: U.S. Urology Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 215: U.S. Urology Devices Market: Strategic Recommendations for Urology Practices and Ambulatory Surgery Centers
TABLE 216: U.S. Urology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 217: U.S. Urology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 218: U.S. Urology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 219: U.S. Urology Devices Market: Go-to-Market Strategy Considerations
TABLE 220: U.S. Urology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 221: U.S. Urology Devices Market: Clinical Evidence and Reimbursement Strategy
TABLE 222: U.S. Urology Devices Market: State-Level Commercial Prioritization
TABLE 223: U.S. Urology Devices Market: Physician Training and Key Opinion Leader Strategy
TABLE 224: U.S. Urology Devices Market: Service, Maintenance, and Customer-Support Strategy
TABLE 225: U.S. Urology Devices Market: Acquisition and Partnership Opportunity Framework
TABLE 226: U.S. Urology Devices Market: Scope Limitation
TABLE 227: U.S. Urology Devices Market: Data Use Limitation
TABLE 228: U.S. Urology Devices Market: Forecasting Limitation
TABLE 229: U.S. Urology Devices Market: Legal Disclaimer
TABLE 230: U.S. Urology Devices Market: Third-Party Data Disclaimer
TABLE 231: U.S. Urology Devices Market: Regulatory and Reimbursement Disclaimer
TABLE 232: U.S. Urology Devices Market: Company and Product Information Disclaimer

List of Figures

FIGURE 1: U.S. Urology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Urology Devices Market Ecosystem
FIGURE 4: U.S. Urology Devices Market Stakeholder Framework
FIGURE 5: Market Attractiveness Analysis
FIGURE 6: U.S. Urology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. Urology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Urology Devices Market Year-Wise Growth Curve, 2021–2035
FIGURE 9: U.S. Urology Devices Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Hospital Capital Procurement Decision Framework
FIGURE 13: Procedure Migration and Site-of-Care Framework
FIGURE 14: Urology Device Replacement-Cycle Framework
FIGURE 15: PESTEL Analysis
FIGURE 16: Porter’s Five Forces Analysis
FIGURE 17: Value Chain Analysis
FIGURE 18: Supply Chain Analysis
FIGURE 19: FDA Regulatory and CMS Reimbursement Framework
FIGURE 20: Infection Prevention and Endoscope Reprocessing Framework
FIGURE 21: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 22: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Urology Endoscopes and Visualization Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Urinary Catheters and Drainage Products Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Kidney Stone Management Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: BPH and Prostate Treatment Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Urinary Incontinence, Pelvic Floor, and Urodynamic Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 29: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Urolithiasis and Kidney Stone Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Urinary Incontinence and Urinary Retention Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Urologic Cancer Diagnosis and Treatment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Neuro-Urology and Reconstructive Urology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 36: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Ambulatory Surgery Centers and Outpatient Procedure Facilities Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Urology Clinics and Specialty Care Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Diagnostic and Urologic Testing Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Home Healthcare and Long-Term Care Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 43: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Endoscopic and Visualization Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Laser and Energy-Based Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Robotic, Navigation, and Image-Guided Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Implantable and Neuromodulation Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Single-Use, Digital, and Connected Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 50: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Direct Hospital and Health System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Distributor and Specialty Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Ambulatory, Physician-Office, and Homecare Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 57: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Regional Urology Procedure Volume and Hospital Infrastructure Analysis
FIGURE 59: West Region U.S. Urology Devices Market Share and Leading Players, 2025
FIGURE 60: West Region Market Share Analysis by State, 2025
FIGURE 61: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: California Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Washington Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Arizona Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Colorado Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Oregon Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Utah Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Nevada Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: New Mexico Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Idaho Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Montana Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Wyoming Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Alaska Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Hawaii Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Northeast Region U.S. Urology Devices Market Share and Leading Players, 2025
FIGURE 76: Northeast Region Market Share Analysis by State, 2025
FIGURE 77: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New York Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Massachusetts Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New Jersey Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Pennsylvania Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Connecticut Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Maine Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Vermont Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: New Hampshire Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Rhode Island Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Delaware Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: South Region U.S. Urology Devices Market Share and Leading Players, 2025
FIGURE 89: South Region Market Share Analysis by State, 2025
FIGURE 90: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Texas Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Florida Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Georgia Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: North Carolina Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Tennessee Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: South Carolina Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Alabama Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Mississippi Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Louisiana Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Arkansas Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Kentucky Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Oklahoma Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Virginia Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Maryland Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: West Virginia Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: District of Columbia Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Midwest Region U.S. Urology Devices Market Share and Leading Players, 2025
FIGURE 108: Midwest Region Market Share Analysis by State, 2025
FIGURE 109: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Illinois Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Ohio Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Michigan Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Minnesota Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Indiana Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Wisconsin Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Missouri Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Iowa Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Kansas Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Nebraska Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: North Dakota Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: South Dakota Urology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 122: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 123: Company Positioning Matrix
FIGURE 124: Key Player Product Portfolio Benchmarking
FIGURE 125: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 126: Urology Device Innovation Roadmap
FIGURE 127: Single-Use Urology Endoscopy Adoption Roadmap
FIGURE 128: Advanced Laser Lithotripsy Technology Opportunity Map
FIGURE 129: Robotic BPH Treatment Platform Growth Roadmap
FIGURE 130: Sacral Neuromodulation and Continence Technology Roadmap
FIGURE 131: Future Market Scenario Analysis, 2026–2035
FIGURE 132: Disruptive Technologies Impact Matrix
FIGURE 133: Emerging Business Trends Matrix
FIGURE 134: Product White-Space Opportunity Map
FIGURE 135: Investment Prioritization Matrix
FIGURE 136: Strategic Growth Roadmap for U.S. Urology Device Companies
FIGURE 137: Go-to-Market Strategy Framework
FIGURE 138: Product Positioning and Portfolio Expansion Framework
FIGURE 139: Clinical Evidence and Reimbursement Strategy Framework
FIGURE 140: State-Level Commercial Prioritization Matrix
FIGURE 141: Report Scope and Disclaimer Framework